Cancer Council Victoria | Victorian Cancer Trials Link

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas

Clinical summary

This trial is evaluating the safety, pharmacokinetics and efficacy of RP4014, to be administered at escalating doses starting at 25 mg. This trial has a single group assignment.

Conditions

This trial is treating patients with Lymphoma

Trial Acronym

Trial Identifiers

NCT03119467

Cancer

Acute Lymphoblastic Lymphoma, B-Cell Non Hodgkin Lymphoma, Diffuse Large Cell Lymphoma, Follicular Lymphoma, Hodgkin's Disease (Hodgkin's Lymphoma), Lymphoma, Mantle Cell Lymphoma, Skin Lymphoma, T-Cell Lymphoma

Age: 18+

Phase: I

For full trial details, visit trials.cancervic.org.au/details/vctl_nct03119467